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verse events were nausea and vomiting.  Conclusion: Gefi-
tinib in combination with chemotherapy did not improve ef-
ficacy in advanced urothelial cancer.  © 2015 S. Karger AG, Basel 
 Introduction 
 Urothelial carcinoma remains one of the leading 
causes of cancer mortality and morbidity in Europe  [1] 
and the United States  [2] . Approximately, 20–40% of 
newly diagnosed patients present with, or go on to de-
velop, invasive disease  [3] . Outcomes in these patients are 
particularly poor, with five-year survival rates for patients 
presenting with regional or distant metastases of 35 and 
5%, respectively  [2] .
 In other malignancy types, such as non-small cell lung 
cancer (NSCLC), breast cancer, colorectal cancer, gastro-
intestinal stromal tumor, and renal cell cancer, the use of 
targeted therapies has had a major impact in terms of im-
proved outcomes. Over the past decade, drugs such as 
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 Abstract 
 Introduction: This phase II trial evaluated the efficacy and 
safety of the epidermal growth factor receptor (EGFR) tyro-
sine kinase inhibitor, gefitinib, in combination with first-line 
chemotherapy in advanced urothelial cancer.  Methods: 
Chemotherapy-naïve patients with advanced or metastatic 
urothelial carcinoma were randomized 1: 1:1 to receive six 
cycles of chemotherapy (gemcitabine 1,250 mg/m 2 on days 
1 and 8, and cisplatin 70 mg/m 2 on day 1 of every cycle) con-
comitantly with gefitinib 250 mg/day (arm A); or with 
 sequential gefitinib (arm B); or alone (arm C). The primary 
endpoint was the time to progression (TTP).  Results: A total 
of 105 patients received study treatment. Median TTP for 
arms A, B, and C were 6.1, 6.3, and 7.8 months, respectively. 
There were no significant differences between treatment 
arms for any outcomes measured. The most common ad-
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sunitinib, sorafenib, bevacizumab, imatinib, gefitinib, ce-
tuximab, and trastuzumab have contributed to an in-
creased clinical benefit observed in patients with cancer 
 [4–7] . However, for patients with advanced or metastatic 
urothelial cancer, there are no approved targeted thera-
pies and chemotherapy remains the standard of care  [8] .
 The epidermal growth factor receptor (EGFR) has 
been implicated in the progression of urothelial carcino-
ma  [9] , and thus can be considered a potential therapeutic 
target. Previous studies report EGFR expression in uro-
thelial carcinoma being in the range of 27 to 91%  [10–15] . 
Furthermore, EGFR status has been shown to be associ-
ated with invasive disease  [10] and predictive of progres-
sion and survival  [12, 13, 16–18] .
 Gefitinib, a selective EGFR tyrosine kinase inhibitor 
(TKI), has shown activity in preclinical  [19] and clinical 
 [20] studies in urothelial carcinomas. In addition, the 
combination therapy of gefitinib with gemcitabine and 
cisplatin has shown activity in other tumors  [21–23] .
 The current study was initiated to further investigate 
the efficacy and safety of concomitant or sequential gefi-
tinib compared with standard chemotherapy alone in 
chemotherapy-naïve patients with advanced urothelial 
carcinoma.
 Patients and Methods 
 Patients 
 Patients eligible for inclusion were  ≥ 18 years old, having re-
ceived no previous chemotherapy or other systemic antitumor 
therapy, estimated creatinine clearance (COCKCROFT) <60 ml/
min, with histologically or cytologically confirmed, measurable, 
advanced, or metastatic transitional cell carcinoma of the urothe-
lium and a World Health Organization (WHO) performance sta-
tus of 0 to 1. The study was conducted from December 2003 to 
October 2008 in accordance with relevant local regulations, the 
International Conference on Harmonisation Guidelines for 
Good Clinical Practice, and the ethical principles laid down in the 
Declaration of Helsinki  [24] . All patients provided written in-
formed consent before any study-related procedures were per-
formed.
 Study Objectives 
 The primary objective of the study was to assess the activity of 
gefitinib (250 mg) in patients with advanced or metastatic transi-
tional cell carcinoma of the urothelium, administered once daily 
continuously in addition to standard chemotherapy or adminis-
tered after completion of standard chemotherapy. This was mea-
sured by time to progression (TTP), based on Response Evaluation 
Criteria In Solid Tumors (RECIST) v1.0. Tumor response assess-
ments were performed by each investigator.
 The secondary objectives of the study included evaluating the 
overall response rate (ORR), time to treatment failure (TTF), over-
all survival (OS), disease control rate (DCR), and duration of re-
sponse. The safety objective of the study was to measure the safety 
and tolerability for each treatment arm. Serious adverse events 
(AEs) were defined as an AE that resulted in death; was life-threat-
ening; resulted in hospitalization; resulted in prolonged disability/
incapacity; or a congenital abnormality or birth defect. Patients 
who experienced progression or toxicity were followed up for sur-
vival until withdrawal of study medication of the last patient (study 
closure). Patients who withdrew were followed up every 12 weeks 
for survival information until death.
 Study Design 
 This was a phase II, multicenter, open-label, randomized study 
of gemcitabine and cisplatin with or without concomitant or se-
quential gefitinib. Patients were randomized (1: 1:1) into one of 
three arms. Across all three arms, standard chemotherapy was 
administered in 21-day cycles consisting of gemcitabine 1,250 
mg/m 2 on days 1 and 8 and cisplatin 70 mg/m 2 on day 1. Arm A 
received six cycles of gemcitabine and cisplatin plus concomitant 
gefitinib 250 mg once daily, followed by gefitinib 250 mg once 
daily as maintenance therapy until tumor progression. Arm B re-
ceived six cycles of gemcitabine and cisplatin followed by gefitinib 
250 mg once daily until progression; and arm C received six cycles 
of gemcitabine and cisplatin followed by observation until pro-
gression.
 An extension group, comprising patients in arm B and arm C 
who were unable to complete six cycles of chemotherapy either due 
to toxicity or objective disease progression, received gefitinib 250 
mg once daily until further progression. Estimating the efficacy 
and safety profile of patients in the extension arm was a further 
exploratory endpoint.
 Statistical Analysis 
 For the intent-to-treat (ITT) population, 102 patients (34 per 
treatment group) were required. Assuming a drop-out rate of 
 approximately 20%, the sample size had to be 125 patients. The 
sample size was determined based on the following assumptions: 
7.4 months’ TTP with gemcitabine and cisplatin alone  [25] , cor-
responding to an 18-month progression-free rate of 18.5% (ex-
ponential survival function); 30% maximum benefit of addition-
al use of gefitinib (sequentially or concomitantly), resulting in a 
TTP of 9.6 months (27.3% progression-free patients) in the best 
treatment arm. The goal was to have a probability of 75% of con-
cluding that further evaluation of gefitinib plus gemcitabine and 
cisplatin on the improvement of TTP in patients with advanced 
or metastatic transitional cell carcinoma of the urothelium is 
warranted, based on the observed difference in the response rates 
between the treatment arms using a selection design with three 
arms  [26] .
 Standard summary statistics were used to describe variables. 
ORRs and DCRs were summarized with proportions together with 
exact two-sided 95% confidence intervals (CI). Durations (TTP, 
OS, and duration of response) were summarized using Kaplan-
Meier methods. The log-rank test was used to assess the differ-
ences between treatment arms.
 Efficacy endpoints were analyzed using the ITT population. 
Safety endpoints were analyzed using the all-subjects-treated 
(AST) population.
 Due to the selection design of this study, the trial was noncom-
parative in the strong confirmatory statistical sense. The goal of the 
study was to select the most efficient of the three treatment arms, 
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which would be used in a subsequent study. Despite the insuffi-
cient statistical power to assess trends in patient response to the 
study treatments, a log-rank test was performed for an exploratory 
comparison of all three target variables.
 Results 
 Study Population 
 A total of 111 patients from 19 research sites in 
 Germany and Switzerland were screened. Of these, 105 
patients received study treatment (AST population). 
Eighteen of the 105 patients were excluded from the ITT 
population: three patients as a result of violation of the 
inclusion/exclusion criteria, and 15 patients as a conse-
quence of missing their tumor assessment. Thus, a total 
of 87 patients were included in the ITT analysis ( fig. 1 ).
 Disease characteristics at baseline were representative 
of a population with histologically or cytologically con-
firmed, measurable, advanced, or metastatic transitional 
cell carcinoma of the urothelium. Two patients who had 
squamous cell histology were erroneously enrolled. The 
majority had metastatic disease (arm A 90%, arm B 81%, 
arm C 83%), and a WHO performance status of 0 or 1 
( table 1 ). Two patients who had a WHO performance sta-
tus of 2 were incorrectly enrolled.
Arm A
Received intervention (n = 35)
 Included in ITT analysis
 (n = 29)
a
 (n = 6)
Arm B
Received intervention (n = 37)
 Included in ITT analysis
 (n = 30)
a
 (n = 7)
Arm C
Received intervention (n = 33)
 Included in ITT analysis
 (n = 28)
a
 (n = 5)
Discontinued intervention (n = 33)
Due to:
Discontinued intervention (n = 37)
Due to:
  consent (n = 4)
 (n = 0)
 consent (n = 2)
 (n = 0)
Discontinued intervention (n = 34)
Due to:
 consent (n = 5)
Included in analysis (n = 35) Included in analysis (n = 37) Included in analysis (n = 33)
 Fig. 1. CONSORT diagram.  a Patients excluded from the ITT analysis as a result of inclusion/exclusion criteria vio-
lation (n = 3) and missing tumor assessments (n = 15) – indeterminate across all three arms. ITT = Intent-to-treat. 
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 Patient demographics were generally consistent across 
the treatment arms; all patients were of Caucasian origin, 
and the majority were elderly males. Almost all patients 
had undergone prior surgery, with only four having re-
ceived prior radiotherapy.
 The most common surgery performed was transure-
thral resection of the bladder (41.7%). Other operations 
included cystectomy, nephro-urectomy, prostatectomy, 
and laparotomy.
 In total, 19 patients (63.3%) received gefitinib in arm 
B after completing six cycles of chemotherapy. The exten-
sion arm included only two patients (1.9%), who were 
treated with gefitinib; the exploratory analysis was there-
fore not conducted due to the small sample size.
 Efficacy Results 
 Median TTP for patients in arm A was 6.1 months 
(95% CI 4.39–9.40), in arm B 6.3 months (95% CI 5.24–
7.80), and in arm C 7.8 months (95% CI 6.19–9.63). An 
exploratory analysis indicated that there were no statisti-
cally significant differences between the treatment arms 
( fig. 2 ).
 Similarly, there were no significant differences be-
tween the treatment arms for any of the secondary end-
points. Forty-five of the 87 patients treated with gefitinib 
had an objective tumor response, according to RECIST 
criteria, comprising 40 partial responders and five com-
plete responders. The ORRs were 58.6, 53.3, and 42.8% in 
arms A, B, and C, respectively ( table 2 ).
 Fig. 2. Kaplan-Meier plot of time to progression. 
Table 2.  Response rates
 Number of patients (%)
arm A 
(n = 29)
arm B 
(n = 30)
arm C 
(n = 28)
ORR 17 (58.6) 16 (53.3) 12 (42.8)
PR 15 (51.7) 15 (50.0) 10 (35.7)
CR 2 (6.8) 1 (3.3) 2 (7.1)
SD 12 (42.8) 10 (35.7) 8 (28.5)
 CR = Complete response; ORR = overall response rate; PR = 
partial response; SD = stable disease.
Table 1.  Baseline demographics and disease characteristics
 Number of patients (%)
arm A arm B arm C
Population, n (%)
All patients screened 36 (100.0) 38 (100.0) 37 (100.0)
All patients treated 35 (97.2) 37 (97.4) 33 (89.2)
Intent-to-treat 29 (80.6) 30 (78.9) 28 (75.7)
Sex, n (%)
Female 12 (34.3) 12 (32.4) 7 (21.2)
Male 23 (65.7) 24 (64.9) 26 (78.8)
Missing 0 1 (2.7) 0
Age, years
Mean ± SD 61.8±11.3 64.7±9.5 61.4±9.7
Median 66 66 63
Range 41–84 45–80 42–78
Race, n (%)
Caucasian 35 (100.0) 37 (100.0) 33 (100.0)
WHO performance status
0 20 (58.8) 17 (45.9) 19 (59.4)
1 13 (38.2) 19 (51.4) 13 (40.6)
2 1 (2.9) 1 (2.7) 0
Missing 1 (2.7) 0 (0.0) 1 (2.7)
Histology, n (%)
Transitional cell 28 (80.0) 31 (83.8) 28 (84.9)
Squamous cell 0 1 (2.7) 1 (3.0)
Adenoid 2 (5.7) 0 0
Unknown 4 (11.4) 4 (10.8) 2 (6.1)
Missing 1 (2.9) 1 (2.7) 2 (6.1)
Any tumor-related 
surgery
Yes 35 (100.0) 34 (91.9) 31 (93.4)
No 0 3 (8.1) 1 (3.0)
Missing 0 0 1 (3.0)
Any tumor-related radiotherapy
Yes 0 3 (8.1) 1 (3.0)
No 35 (100.0) 33 (89.2) 29 (87.9)
Missing 0 1 (2.7) 3 (9.1)
 SD = Standard deviation; WHO = World Health Organization.
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 The median TTF for patients in arms A, B, and C was 
5.9 months (95% CI 4.36–9.37), 5.9 months (95% CI 
3.44–7.11), and 5.6 months (95% CI 3.54–8.59), respec-
tively ( fig. 3 ). The median OS for patients in arm A was 
13.3 months (95% CI 10.49–19.24), in arm B 8.5 months 
(95% CI 6.95–14.49), and in arm C 15.9 months (95% CI 
10.88–31.27) ( fig. 4 ).
 Measurements of target and non-target lesions as per 
RECIST were performed at regular intervals (every two 
cycles). However, the investigator’s assessment of the 
overall response was not collected at each individual time 
point. A statement of the best response achieved during 
the study was collected at the end of the last chemother-
apy visit. Thus, the DCR and duration of response were 
not assessed.
 Toxicity 
 All patients treated in the study experienced at least one 
AE, the most common events being nausea, vomiting, leu-
kopenia, and fatigue. Most AEs were characterized by 
mild-to-moderate intensity (Common Toxicity Criteria 
(CTC) grades 1 and 2). There were 60 serious AEs report-
ed in 105 patients (57.14%, AST population), the most fre-
quent being pancytopenia, pyrexia, and vomiting ( table 3 ).
 In arm A, there were 109 AEs considered gefitinib-
related, according to investigator assessment. Of these, 
rash (CTC grade 1 or 2) was the most common (40.0% of 
patients). There were 13 gefitinib-related SAEs in arm 
A. In arm B, 23 AEs were considered by investigators as 
 likely to be related to gefitinib, of which diarrhea (CTC 
grade 1 or 2, except in one patient) was the most common 
(10.8% of patients). There were two gefitinib-related 
SAEs in arm B.
 Overall, there were 152 cases of therapy delay or dose 
reduction due to AEs across all arms of the study. There 
were 17 dose interruptions, most frequently due to toxic-
ity. There were no dose interruptions in arm C. The most 
common reason for study discontinuation was death: 
10 patients (28.5%) in arm A; 21 patients (56.8%) in arm 
B; and 17 patients (51.5%) in arm C. In total, there were 
61 deaths during the course of the study: 19 (54.3%), 23 
(62.2%), and 19 (57.6%) in arms A, B, and C, respectively. 
The most common cause of death was urothelial carci-
noma disease progression (17, 20, 19 in arms A, B, and C, 
respectively). Deaths not considered related to disease 
progression were caused by septic shock (one patient) 
and apoplexy (one patient) in arm A, and pulmonary in-
sufficiency (one patient), cardiorespiratory failure (one 
patient), and unknown cause (one patient) in arm B.
 Discussion 
 Cisplatin-based chemotherapy is the standard of care 
in patients with advanced urothelial carcinoma. Specifi-
cally, gemcitabine-cisplatin combination chemotherapy 
has been shown to provide the best efficacy and tolerabil-
ity, replacing methotrexate, vinblastine, doxorubicin, and 
cisplatin as the treatment of choice  [27] . Efforts to im-
prove outcomes in this patient group have focused on the 
addition of a third drug. It has been proposed that the ad-
dition of a targeted therapeutic agent would result in im-
 Fig. 3. Kaplan-Meier plot of time to treatment failure.   Fig. 4. Kaplan-Meier plot of overall survival. 
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proved efficacy and minimal toxicity, as observed in other 
tumor types  [4–7] . Presently, there are no approved tar-
geted therapies for urothelial carcinoma; however, a num-
ber of potential molecular targets are being investigated 
in  clinical research, including the EGFR family, multi- 
targeted TKIs, angiogenesis (vascular endothelial growth 
factor (VEGF) and VEGFR), fibroblast growth factor re-
ceptor (FGFR), RTK-Ras/Raf/MAPK, PI3K/AKT/mTOR, 
and anti-CTLA4 antibody (reviewed in  [28–30] ).
 The aim of the current study was to establish whether 
the efficacy of the gemcitabine-cisplatin regimen would 
be improved with the addition of the EGFR-TKI gefitinib. 
This combination and dosing (gefitinib 250 mg, gem-
citabine 1,250 mg/m 2 ) appeared to be highly active and 
well tolerated in a phase I study in patients with advanced 
solid tumors  [21] . The gemcitabine dose of 1,250 mg/m 2 
has also been shown to be well tolerated in patients with 
transitional cell carcinoma of the bladder  [31, 32] . Our 
results did not show any significant benefits with either 
concomitant or sequential gefitinib, although a trend to-
wards higher response rates was observed. In our study, 
the ORRs in both gefitinib arms (arms A and B) were 
similar to those reported in the gemcitabine-cisplatin 
only arm (49.4%) in a phase III trial  [33] and slightly high-
er than those reported in a phase II trial of gemcitabine-
cisplatin given concomitantly with gefitinib in patients 
with advanced urothelial carcinoma (58.6 and 53.3% vs. 
42.6%)  [34] . Unintentional selection bias may account for 
the comparatively low response rates. It is probable that 
the OS data were influenced by the nature of subsequent 
treatments; however, information on these treatments 
was not collected, and this is therefore recognized as a 
limitation of the OS findings.
 The toxicity profiles of both gefitinib arms (arms A 
and B) were similar to that observed for gemcitabine-cis-
platin alone (arm C). All AEs were consistent with the 
Preferred term  Number of patientsa (%)
arm A
(n = 35)
ar m B
(n = 37)
arm C
(n = 33)
Any adverse event
Alopecia 4 (11.4) 13 (35.1) 10 (30.3)
Anemia 10 (28.6) 18 (48.6) 10 (30.3)
Anorexia 5 (14.3) 6 (16.2) 6 (18.2)
Asthenia 2 (5.7) 1 (2.7) 5 (15.2)
Back pain 6 (17.1) 0 3 (9.1)
Cancer pain 1 (2.9) 4 (10.8) 2 (6.1)
Cardiac discomfort 0 4 (10.8) 0
Chills 0 0 6 (18.2)
Constipation 5 (14.3) 6 (16.2) 3 (9.1)
Cystitis 2 (5.7) 5 (13.5) 0
Diarrhea 17 (48.6) 10 (27) 5 (15.2)
Drug hypersensitivity 1 (2.9) 1 (2.7) 6 (18.2)
Epistaxis 2 (5.7) 4 (10.8) 3 (9.1)
Fatigue 8 (22.9) 25 (67.6) 27 (81.8)
General physical
health deterioration 4 (11.4) 5 (13.5) 1 (3)
Hematuria 2 (5.7) 5 (13.5) 0
Hemoglobin decreased 5 (14.3) 2 (5.4) 4 (12.1)
Hemoptysis 0 5 (13.5) 0
Headache 1 (2.9) 7 (18.9) 5 (15.2)
Hyperhidrosis 0 5 (13.5) 0
Hypertension 3 (8.6) 5 (13.5) 1 (3)
Leukopenia 21 (60.0) 20 (54.1) 26 (78.8)
Nausea 31 (88.6) 34 (91.9) 36 (109.1)
Neutropenia 13 (37.1) 7 (18.9) 8 (24.2)
Pain 6 (17.1) 2 (5.4) 2 (6.1)
Pancytopenia 8 (22.9) 7 (18.9) 2 (6.1)
Preferred term  Number of patientsa (%)
arm A
(n = 35)
ar m B
(n = 37)
arm C
(n = 33)
Pleural effusion 0 5 (13.5) 0
Pneumonia 4 (11.4) 5 (13.5) 0
Pruritus 3 (8.6) 4 (10.8) 1 (3.0)
Pyrexia 10 (28.6) 11 (29.7) 7 (21.2)
Rash 15 (42.9) 6 (16.2) 3 (9.1)
Renal failure 8 (22.9) 0 0
Stomatitis 1 (2.9) 2 (5.4) 6 (18.2)
Subclavian vein 
thrombosis 4 (11.4) 0 0
Thrombocytopenia 9 (25.7) 4 (10.8) 6 (18.2)
Urinary tract infection 1 (2.9) 12 (32.4) 6 (18.2)
Visual disturbance 5 (14.3) 0 0
Vomiting 23 (65.7) 20 (54.1) 25 (75.8)
Any serious adverse event
Anemia 2 (5.7) 4 (10.8) 0
Neutropenia 4 (11.4) 0 0
Pancytopenia 5 (14.3) 7 (18.9) 0
Pleural effusion 0 4 (10.8) 0
Pneumonia 4 (11.4) 3 (8.1) 0
Pyrexia 0 4 (10.8) 3 (9.1)
Renal failure 4 (11.4) 0 0
Visual disturbance 4 (11.4) 0 0
Vomiting 5 (14.3) 1 (2.7) 2 (6.1)
 a Patients who experienced separate adverse events of different 
common toxicity criteria grades may have been counted more than 
once.
Table 3.  Adverse events and serious adverse events regardless of causality occurring in >10% frequency in any arm
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tolerability profiles of the study drugs and the conditions 
associated with progression of urothelial carcinoma.
 At the time this study was conducted, the role played 
by mutations in the  EGFR gene in the response to gefi-
tinib was not fully understood and  EGFR mutation test-
ing was not typically performed in urothelial carcinoma. 
Subsequently, studies in advanced NSCLC have demon-
strated that certain somatic  EGFR mutations predict for 
an improved tumor response to gefitinib treatment, com-
pared with wild-type disease. Consequently,  EGFR muta-
tion testing is now part of routine investigations in ad-
vanced NSCLC  [35, 36] .
 A possible explanation for the lack of efficacy observed 
in the gefitinib arms in comparison with the control arm 
in the current study could be due to the absence of  EGFR 
mutations conferring sensitivity to EGFR-TKI; however, 
as retrospective testing is not possible, this cannot be ver-
ified. In addition, EGFR-TKI-sensitizing mutations in 
urothelial carcinoma are thought to be extremely rare – a 
number of studies investigating this tumor type have 
been unable to determine their existence  [37–41] . Pre-
clinical studies in urothelial carcinoma have found that 
the tumor cell-growth inhibition effect of gefitinib is in-
dependent of both the mutation status and protein level 
of EGFR  [37, 42] . Inoue et al. also suggested that upregu-
lation of YY1 and  E-cadherin may be implicated in gefi-
tinib-sensitivity observed in certain bladder cancer cell 
lines  [42] . In addition, uncoupling of mitogenic pathways 
downstream of EGFR, due to PDGFRβ activation, has 
been shown to cause resistance to gefitinib in bladder 
cancer cell lines  [43] .
 Targeting multiple pathways in order to improve treat-
ment outcomes in advanced urothelial cancer has also been 
suggested. Several studies have proposed that co-expres-
sion patterns of EGFR alongside other members of the 
EGFR super-family or the tyrosine kinase recepteur 
d’origine nantais (RON) may be a better prognostic indica-
tor than any of the receptors alone in urothelial carcinoma 
 [15, 44, 45] . Hsu et al. have also presented clinical evidence 
that EGFR and RON are able to activate one another in 
bladder cancer cell lines  [45] . Conflicting results have been 
reported for the VEGFR and EGFR dual inhibitor vande-
tanib. Greater antitumor activity was exhibited for vande-
tanib than gefitinib in human bladder cancer cell lines, and 
vandetanib also displayed synergism with cisplatin  [39] . 
However, vandetanib in combination with docetaxel did 
not exhibit a significant improvement in progression-free 
survival in patients with advanced urothelial cancer  [46] .
 Data indicate that radical treatment of the tumor, even 
in a metastatic setting, may improve outcomes  [47] , and 
it would be interesting to investigate whether there were 
differences in findings between the patients who received 
transurethral resection, radical cystectomy, and radiation 
alone. Unfortunately, this was not a planned outcome for 
this study and the data are not available; however, it is 
recommended that this analysis should be included in 
 future trials of this nature.
 In summary, gefitinib did not contribute to better pa-
tient outcomes in this population of metastatic urothelial 
carcinoma; platinum-based chemotherapy remains the 
cornerstone of treatment. However, it is hoped that by 
gaining a better understanding of the different molecular 
pathways that influence disease progression in this tumor 
indication, more effective targeted therapies may be de-
veloped. An assessment of EGFR status would be of po-
tential value in future studies of EGFR/TKIs in urothelial 
carcinoma; identification of patients that is most likely to 
benefit from these therapies may also result in improved 
clinical outcomes.
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